Litmus email source
Copy source
<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office"> <head> <title>Novo Nordisk</title> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"> <meta name="viewport" content="width=device-width"> <!--[if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:AllowPNG/> <o:PixelsPerInch>96</o:PixelsPerInch> </o:OfficeDocumentSettings> </xml><![endif]--> <!--[if (gte mso 15)|(IE)]> <style type="text/css"> table { border-collapse: collapse; border-spacing: 0; mso-line-height-rule: exactly; mso-margin-bottom-alt: 0; mso-margin-top-alt: 0; mso-table-lspace: 0pt; mso-table-rspace: 0pt;} td {mso-hyphenate: none;} </style> <![endif]--> <!--[if gte mso 9]> <style> sup, sub { font-size: 100% !important; } </style> <![endif]--> <style type="text/css"> @media screen { @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 400; font-display: fallback; src: local('Noto Sans Italic'), local('NotoSans-Italic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0OIpQlx3QUlC5A4PNr4ARCQ_mu72Bi.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: italic; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold Italic'), local('NotoSans-BoldItalic'), url('https://fonts.gstatic.com/s/notosans/v9/o-0TIpQlx3QUlC5A4PNr4Az5ZuyDzW1IPrie.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 400; font-display: fallback; src: local('Noto Sans'), local('NotoSans'), url('https://fonts.gstatic.com/s/notosans/v9/o-0IIpQlx3QUlC5A4PNr5TRASf6M7Q.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } @font-face { font-family: 'Noto Sans'; font-style: normal; font-weight: 700; font-display: fallback; src: local('Noto Sans Bold'), local('NotoSans-Bold'), url('https://fonts.gstatic.com/s/notosans/v9/o-0NIpQlx3QUlC5A4PNjXhFVZNyBx2pqPA.woff2') format('woff2'); unicode-range: U+0000-00FF, U+0131, U+0152-0153, U+02BB-02BC, U+02C6, U+02DA, U+02DC, U+2000-206F, U+2074, U+20AC, U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; } } #outlook a { padding: 0; } .ReadMsgBody { width: 100%; } .ExternalClass { width: 100%; } .ExternalClass, .ExternalClass p, .ExternalClass span, .ExternalClass font, .ExternalClass td, .ExternalClass div { line-height: 100%; } body, table, td, a { -webkit-text-size-adjust: 100%; -ms-text-size-adjust: 100%; } table, td { mso-table-lspace: 0pt; mso-table-rspace: 0pt; } img { -ms-interpolation-mode: bicubic; } body { margin: 0; padding: 0; } img { border: 0; height: auto; line-height: 100%; outline: none; text-decoration: none; } table { border-collapse: collapse !important; } body { height: 100% !important; margin: 0 auto !important; padding: 0; width: 100% !important; } .default-blue-text a { color: #001965; text-decoration: none; } .default-blue-link-text a { color: #025edc; text-decoration: underline; } @media screen and (max-width: 670px) { img.img-responsive { width: 100% !important; height: auto !important; } } @media screen and (max-width: 480px) { .img-mobile-width-240 { width: 240px !important; height: auto !important; } } @media screen and (max-width: 670px) { table.mobile-hide, td.mobile-hide, img.mobile-hide, .mobile-hide { display: none !important; } } @media screen and (max-width: 670px) { div.mobile-only-content { display: block !important; max-height: none !important; max-width: 100% !important; height: auto !important; width: auto !important; visibility: visible !important; } } @media screen and (max-width: 670px) { .email-container { max-width: 610px !important; width: 100% !important; } } @media screen and (max-width: 670px) { .col-80 { width: 100% !important; } } @media screen and (max-width: 670px) { .mfs-11 { font-family: "Noto Sans", Apis, Arial, Helvetica, sans-serif; font-weight: normal; color: #001965; font-size: 11px !important; line-height: 1.4; } } @media screen and (max-width: 670px) { .text-center { text-align: center !important; } } @media screen and (max-width: 670px) { .mpb-15 { padding-bottom: 15px !important; } .mpb-16 { padding-bottom: 16px !important; } } @media screen and (max-width: 670px) { .email-gutter { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only-30 { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-desktop-only-50 { padding-right: 0 !important; padding-left: 0 !important; } } @media screen and (max-width: 670px) { .email-gutter-15 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-20 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-50 { padding-right: 20px !important; padding-left: 20px !important; } .email-gutter-100 { padding-right: 20px !important; padding-left: 20px !important; } } @media screen and (max-width: 670px) { .email-gutter-mobile-10 { padding-right: 10px !important; padding-left: 10px !important; } } </style> </head> <body style="background-color: #f3f3f4;"> <center style="width: 100%"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color: #f3f3f4;"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter-desktop-only" style="background-color: #f3f3f4; padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="border-bottom: 1px solid #E5E3E6;"> <tr> <td valign="top" class="email-gutter-15" style="padding-bottom: 10px; padding-left: 15px; padding-right: 15px; padding-top: 10px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="top"> <!-- Preheader text --> <div style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 12px;">Guidelines emphasize prompt intervention for suspected bleeds.</div> <!-- Preheader filler spaces --> <div style="display: none; max-height: 0; max-width: 0; width: 0; visibility: hidden; overflow: hidden; font-size: 1px; line-height: 0; mso-hide: all;">  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ </div> </td> <td align="right" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 1.4; width: 100px;"><a href="#" target="_blank" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">View online</a></td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td valign="top"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" class="email-gutter-mobile-10" style="padding-bottom: 10px; padding-top: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding: 0 5px 0 0;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html?showIsi=true" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Important Safety Information</a></td> <td align="center" style="color: #4a4a4a; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4;"> | </td> <td align="center" valign="middle" class="mfs-11" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding: 0 0 0 5px;"><a href="https://www.novo-pi.com/novosevenrt.pdf" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">Prescribing Information</a></td> </tr> </table> </td> </tr> <tr> <td align="center" class="email-gutter" style="padding-left: 30px; padding-right: 30px;"><a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/novoseven-logo.png" width="320" height="90" border="0" alt="NovoSeven® RT Coagulation Factor VIIa (Recombinant) logo." class="img-mobile-width-240" style="display: inline-block;"></a></td> </tr> <tr> <td align="center" class="email-gutter-20" style="padding-bottom: 24px; padding-left: 20px; padding-right: 20px; padding-top: 8px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-style: italic; font-weight: normal; line-height: 18px;">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT (coagulation Factor VIIa, recombinant) is indicated for: Treatment of bleeding episodes and perioperative management in adults and children with congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and treatment of bleeding episodes and perioperative management in adults with acquired hemophilia.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/main-image-desktop.jpg" width="670" height="304" alt="Image of health care professional" class="mobile-hide" style="display: block;"> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/main-image-mobile.jpg" width="750" height="854" alt="Image of health care professional" class="img-responsive" style="display: block; max-width: 610px;"> </div> <!--<![endif]--> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 12px; padding-left: 30px; padding-right: 30px; padding-top: 32px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" class="email-gutter-desktop-only-50" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 36px; font-weight: normal; line-height: 44px; padding-bottom: 28px; padding-left: 50px; padding-right: 50px;">NovoSeven<sup style="font-size: 60%; line-height: 1;">®</sup> RT is the #1 prescribed bypassing agent used in hospitals<sup style="font-size: 60%; line-height: 1;">2</sup></td> </tr> <tr> <td align="center" style="padding-bottom: 8px;"> <table border="0" cellpadding="0" align="left" cellspacing="0" width="100%"> <tr> <td align="left" valign="middle" width="75" style="padding-bottom: 16px; width: 75px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/icon-bleeds.png" width="65" height="70" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="middle" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 16px;">Addressing bleeds, whenever they occur</td> </tr> <tr> <td align="left" valign="top" width="75" style="padding-bottom: 16px; width: 75px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/icon-safety.png" width="65" height="70" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="top" style="padding-bottom: 16px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 4px; padding-top: 8px;">A well-established safety profile</td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; padding-bottom: 4px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; padding-bottom: 4px;">Low rate of thrombotic events based on clinical trials and registry data<sup style="font-size: 70%; line-height: 1;">3</sup></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" width="16" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; width: 16px;"> </td> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; width: 20px;">◦</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px;">Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance. Thrombotic adverse reactions in pivotal clinical trials occurred in 0.2% of bleeding episodes in CHwI, 4% in AH, 0.8% in CFVIId, and <0.2% in GT with refractoriness to platelets.<sup style="font-size: 70%; line-height: 1;">3</sup></td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" width="75" style="padding-bottom: 16px; width: 75px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/icon-indications.png" width="65" height="75" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="top" style="padding-bottom: 16px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 4px; padding-top: 8px;">Proven effective for bleed resolution and surgery across 5 indications<sup style="font-size: 70%; line-height: 1;">3</sup></td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px;">CHAwI, CHBwI, AH, GT with refractoriness to platelet transfusions, and CFVIId</td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" width="75" style="padding-bottom: 16px; width: 75px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/icon-hospital.png" width="65" height="60" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="top" style="padding-bottom: 16px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 4px; padding-top: 8px;">Product features that support hospital use</td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px;">Low-volume dosing and compact packaging to help maximize space<sup style="font-size: 70%; line-height: 1;">3</sup></td> </tr> </table> </td> </tr> <tr> <td align="left" valign="top" width="75" style="padding-bottom: 16px; width: 75px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/icon-years.png" width="65" height="70" border="0" alt="Icon" style="display: block;"></td> <td align="left" valign="top" style="padding-bottom: 16px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 18px; padding-bottom: 4px; padding-top: 8px;">With NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT, the experience continues</td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" valign="top" width="20" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px; width: 20px;">•</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 18px;">>35 years of clinical experience<sup style="font-size: 70%; line-height: 1;">4,a</sup></td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="center" class="text-center" style="padding-bottom: 36px;"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt/efficacy-safety/breakthrough-bleeds.html" target="_blank" style="background-color: #FF0000; border-radius: 44px; color: #ffffff; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; mso-padding-alt: 0; padding-bottom: 12px; padding-left: 30px; padding-right: 30px; padding-top: 12px; text-decoration: none; text-underline-color: #FF0000;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Learn More<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; padding-bottom: 12px;">AH=acquired hemophilia; CFVIId=congenital factor VII deficiency; CHAwI=congenital hemophilia A with inhibitors; CHBwI=congenital hemophilia B with inhibitors; CHwI=congenital hemophilia with inhibitors; GT=Glanzmann’s thrombasthenia.</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px; padding-bottom: 12px;"><sup style="font-size: 70%; line-height: 1;">a</sup>1988: compassionate use initiated in the United States; 1999: FDA approval received for CHwI.<sup style="font-size: 70%; line-height: 1;">3,5</sup></td> </tr> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 1.4; padding-bottom: 8px; padding-top: 36px;">Scroll to see how NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT continues to support your patients.</td> </tr> <tr> <td align="center" style="padding-bottom: 12px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/arrow.png" width="60" height="40" border="0" alt style="display: block;"> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 16px; padding-left: 30px; padding-right: 30px; padding-top: 12px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 15px;"> Important Safety Information</td> </tr> <tr> <td align="center" style="padding: 2px; background-color: #001965;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="border: 2px solid #ffffff; background-color: #ffffff;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="background-color: #ffffff; padding-bottom: 20px; padding-left: 14px; padding-right: 14px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" class="mpb-15" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px; padding-bottom: 10px;">WARNING: THROMBOSIS</td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Serious arterial and venous thrombotic events following administration of NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT have been reported </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 19px;"> Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px; padding-top: 25px;">Warnings and Precautions</td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 24px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Please <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt.html?showIsi=true" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or scroll below for additional Important Safety Information.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 12px; padding-left: 30px; padding-right: 30px; padding-top: 12px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="border-top: 2px solid #ff0000;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" class="email-gutter-desktop-only-30" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 26px; font-weight: normal; line-height: 32px; padding-bottom: 24px; padding-left: 30px; padding-right: 30px; padding-top: 28px;">Proven effective for bleed resolution and surgery across 5 indications—more than any other product<sup style="font-size: 60%; line-height: 1;">3,6-8</sup></td> </tr> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; padding-bottom: 12px;">This chart is not intended to compare efficacy or safety.</td> </tr> </table> </td> </tr> </table> </td> </tr> <tr> <td align="center" class="email-gutter-mobile-10" style="padding-bottom: 8px;"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/chart-desktop.png" width="630" height="560" alt="Indication chart" class="mobile-hide" style="display: block;"> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/chart-mobile.png" width="710" height="1028" alt="Indication chart" class="img-responsive" style="display: block; max-width: 610px;"> </div> <!--<![endif]--> </td> </tr> <tr> <td align="center" class="email-gutter" style="padding-bottom: 20px; padding-left: 30px; padding-right: 30px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 14px;"><sup style="font-size: 70%; line-height: 1;">b</sup>Obizur<sup style="font-size: 70%; line-height: 1;">®</sup> is contraindicated in patients with congenital hemophilia A with inhibitors.<sup style="font-size: 70%; line-height: 1;">7</sup><br><sup style="font-size: 70%; line-height: 1;">c</sup>For patients aged 12 years and older.<sup style="font-size: 70%; line-height: 1;">8</sup></td> </tr> <tr> <td align="center" class="text-center" style="padding-bottom: 24px; padding-top: 24px;"> <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/treatments/novosevenrt/about/why-novosevenrt.html" target="_blank" style="background-color: #ff0000; border-radius: 44px; color: #ffffff; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; mso-padding-alt: 0; padding-bottom: 12px; padding-left: 30px; padding-right: 30px; padding-top: 12px; text-decoration: none; text-underline-color: #ff0000;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Why NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-left: 30px; padding-right: 30px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%" style="background-color: #f7f6f5;"> <tr> <td align="center" class="email-gutter-50" style="padding-bottom: 24px; padding-left: 50px; padding-right: 50px; padding-top: 24px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 22px;">To learn more right away, <a href="https://www.novomedlink.com/rare-bleeding-disorders/products/resources/novonordisk-representative.html" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">request a call with your Rare Blood Institutional Account Manager</a>.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 10px; padding-left: 30px; padding-right: 30px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color: #001965"> <tr> <td align="center" valign="top" class="email-gutter-100" style="padding-bottom: 40px; padding-left: 100px; padding-right: 100px; padding-top: 50px;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 26px; font-weight: bold; line-height: 30px; padding-bottom: 34px;">Have you created an account on novoMEDLINK™?</td> </tr> <tr> <td align="center" style="padding-bottom: 26px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/icon-account.png" width="110" height="100" border="0" alt="Icon" style="display: block;"></td> </tr> <tr> <td align="center" class="email-gutter-desktop-only-30" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 16px; padding-left: 30px; padding-right: 30px;"><b>Keep up</b> with important information about treatments for rare bleeding disorders.</td> </tr> <tr> <td align="center" class="email-gutter-desktop-only-30" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 16px; padding-left: 30px; padding-right: 30px;"><b>Receive</b> the latest news about rare bleeding disorders from Novo Nordisk.</td> </tr> <tr> <td align="center" class="email-gutter-desktop-only-30" style="color: #FFFFFF; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 22px; padding-bottom: 16px; padding-left: 30px; padding-right: 30px;"><b>Download</b>, order, and share educational materials for you and your patients.</td> </tr> <tr> <td align="center" style="padding-bottom: 20px; padding-top: 20px;"><a href="https://www.novomedlink.com/account/create.html" target="_blank" style="background-color: #001965; border: 2px solid #ffffff; border-radius: 44px; color: #ffffff; display: inline-block; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 14px; font-weight: bold; line-height: 20px; mso-padding-alt: 0; padding-bottom: 12px; padding-left: 25px; padding-right: 25px; padding-top: 12px; text-decoration: none; text-underline-color: #001965;"><!--[if mso]><i style="mso-font-width:150%; mso-text-raise:140%;" hidden> </i><span style="mso-text-raise:70%;"><![endif]-->Create Your Account<!--[if mso]></span><i style="mso-font-width:150%;" hidden> ​</i><![endif]--></a> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter mpb-16" style="padding-bottom: 24px; padding-left: 30px; padding-right: 30px; padding-top: 16px;"><table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 15px;">Indications and Usage</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px; padding-bottom: 15px;"> NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for: </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 22px; font-weight: normal; line-height: 1.3; padding-bottom: 20px; padding-top: 10px;">Important Safety Information (cont’d)</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Warnings and Precautions </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur </td> </tr> </table> </td> </tr> <tr> <td align="left"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed </td> </tr> </table> </td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Adverse Reactions</td> </tr> <tr> <td align="left" style="padding-bottom: 15px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Drug Interactions</td> </tr> <tr> <td align="left" style="padding-bottom: 24px;"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td align="left" valign="top" width="25" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 18px; width: 25px;">•</td> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: normal; line-height: 20px;"> Thrombosis may occur if NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT is administered concomitantly with Coagulation Factor XIII </td> </tr> </table> </td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-weight: bold; line-height: 20px; padding-bottom: 15px;">Please <a href="https://www.novo-pi.com/novosevenrt.pdf" target="_blank" style="color: #ff0000; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> for Prescribing Information, including Boxed Warning.</td> </tr> </table> </td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="left" class="email-gutter" style="padding-bottom: 16px; padding-left: 30px; padding-right: 30px;"> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 1.4; padding-bottom: 15px;"><b>References:</b></td> </tr> </table> <table cellspacing="0" cellpadding="0" border="0" width="100%"> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">1.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">Data on file as of 2020. Novo Nordisk, Inc; Plainsboro, NJ.</td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">2.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">Data on file as of 2025. Novo Nordisk, Inc; Plainsboro, NJ.</td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">3.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc.</td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">4.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">Hedner U. History of rFVIIa therapy. <i>Thromb Res</i>. 2010;125(suppl 1):S4-S6.</td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">5.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">Neufeld EJ, Négrier C, Arkhammar P, et al. Safety update on the use of recombinant activated factor VII in approved indications. <i>Blood Rev</i>. 2015;29(suppl1):S34-S41.</td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">6.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">FEIBA<sup style="font-size: 70%; line-height: 1;">®</sup> [package insert]. Lexington, MA: Baxalta US Inc.; 2024.</td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">7.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">Obizur<sup style="font-size: 70%; line-height: 1;">®</sup> [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2024.</td> </tr> <tr> <td width="20" align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">8.</td> <td align="left" valign="top" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;">SEVENFACT<sup style="font-size: 70%; line-height: 1;">®</sup> [package insert]. Louisville, KY: HEMA Biologics, LLC; 2025.</td> </tr> </table> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="email-container" style="background-color: #ffffff; width: 670px;"> <tr> <td align="center" class="email-gutter" style="padding-bottom: 20px; padding-left: 30px; padding-right: 30px; padding-top: 20px;"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td valign="top"> <table cellpadding="0" cellspacing="0" border="0" width="100%" style="border-top: 1px solid #979797"> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 16px; font-style: italic; font-weight: bold; line-height: 22px; padding-bottom: 24px; padding-top: 24px;">Please click on the link to see WAC pricing for the product mentioned above: <a href="https://www.novopricing.com/novosevenrt.html" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;" target="_blank">Product Pricing</a>.</td> </tr> <tr> <td align="left" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 12px; font-weight: normal; line-height: 16px;"><span class="default-blue-link-text">Please do not respond to this email. If you would like to contact us, please <a href="https://www.novonordisk-us.com/contact-us.html" target="_blank" style="color: #025edc; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; text-decoration: underline;">click here</a> or call <span class="default-blue-link-text" style="white-space: nowrap;">1-800-727-6500</span>.</span></td> </tr> </table> </td> </tr> <tr> <td valign="bottom" style="padding-bottom: 20px; padding-top: 20px;"> <table cellpadding="0" cellspacing="0" border="0" align="left" width="100%"> <tr> <td align="left" valign="bottom" style="color: #001965; font-family: 'Noto Sans', Apis, Arial, Helvetica, sans-serif; font-size: 11px; font-weight: normal; line-height: 16px;"><span class="default-blue-text">NovoSeven<sup style="font-size: 70%; line-height: 1;">®</sup> is a registered trademark of Novo Nordisk Health Care AG.<br>novoMEDLINK™ is a trademark of Novo Nordisk A/S.<br>Novo Nordisk is a registered trademark of Novo Nordisk A/S.<br>All other trademarks, registered or unregistered, are the property of their respective owners.<br>© 2026 Novo Nordisk All rights reserved. <span style="white-space: nowrap;">US26NSVN00012</span> <span style="white-space: nowrap;">July 2026</span></span></td> <td align="right" valign="bottom" class="col-80 mobile-hide" style="width: 80px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"></td> </tr> </table> <!--[if !mso]><!--> <div class="mobile-only-content" style="display: none; max-height: 0; max-width: 0; visibility: hidden; width: 0;"> <table cellpadding="0" cellspacing="0" border="0" width="100%"> <tr> <td align="center" valign="top" style="padding-top: 20px;"><img src="https://emails.hemo.novo.cglife.dev/emails/n7-global-campaign-urgency-to-treat-cpd/images/logo-novo-nordisk.png" width="75" height="55" alt="Novo Nordisk logo." style="display: block;"></td> </tr> </table> </div> <!--<![endif]--> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </center> </body> </html>